Patents by Inventor Gabriele Stumm

Gabriele Stumm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of Protein Kinases
    Publication number: 20150011576
    Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
    Type: Application
    Filed: September 22, 2014
    Publication date: January 8, 2015
    Inventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
  • Inhibitors of protein kinases
    Patent number: 8841315
    Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: September 23, 2014
    Assignee: AstraZeneca AB
    Inventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
  • 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
    Publication number: 20130338147
    Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
    Type: Application
    Filed: August 12, 2013
    Publication date: December 19, 2013
    Applicant: Ingenium Pharmaceuticals GmbH
    Inventors: Philipp Wabnitz, Heike Schauerte, Hans Allgeier, Martin Augustin, Lutz Zeitlmann, Michael A. Pleiss, Gabriele Stumm, Anke Mueller, Axel Choidas, Bert Klebl, Gerhard Mueller, Wilfried Schwab, Joelle Le, Jackie Macritchie, Don Simpson
  • INHIBITORS OF PROTEIN KINASES
    Publication number: 20130331407
    Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
    Type: Application
    Filed: August 12, 2013
    Publication date: December 12, 2013
    Applicant: Ingenium Pharmaceuticals GmbH
    Inventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
  • 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
    Patent number: 8507498
    Abstract: The present invention relates to inhibitors of general Formula (I) of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to compounds for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: August 13, 2013
    Assignee: Ingenium Pharmaceuticals GmbH
    Inventors: Philipp Wabnitz, Heike Schauerte, Hans Allgeier, Martin Augustin, Lutz Zeitlmann, Michael A. Pleiss, Gabriele Stumm, Anke Mueller, Axel Choidas, Bert Klebl, Gerhard Mueller, Wilfried Schwab, Joelle Le, Jackie Macritchie, Don Simpson
  • Inhibitors of protein kinases
    Patent number: 8507511
    Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases. formula (I).
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: August 13, 2013
    Assignee: Ingenium Pharmaceuticals GmbH
    Inventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
  • Inhibitors of protein kinases
    Patent number: 8436007
    Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: May 7, 2013
    Assignee: Ingenium Pharmaceuticals GmbH
    Inventors: Philipp Wabnitz, Heike Schauerte, Hans Allgeier, Martin Augustin, Lutz Zeitlmann, Michael A. Pleiss, Gabriele Stumm, Anke Mueller
  • Inhibitors of protein kinases
    Patent number: 8389521
    Abstract: The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceuticals compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases. formula (I).
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: March 5, 2013
    Assignee: Ingenium Pharmaceuticals GmbH
    Inventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
  • 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
    Publication number: 20110306602
    Abstract: The present invention relates to inhibitors of general Formula (I) of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to compounds for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.
    Type: Application
    Filed: April 24, 2008
    Publication date: December 15, 2011
    Inventors: Philipp Wabnitz, Heike Schauerte, Hans Allgeier, Lutz Zeitlmann, Anke Mueller, Martin Augustin, Michael A. Pleiss, Gabriele Stumm, Axel Choidas, Bert Klebl, Gerhard Mueller, Wilfried Schwab, Joelle Le, Jackie Macritchie, Don Simpson
  • INHIBITORS OF PROTEIN KINASES
    Publication number: 20100184789
    Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
    Type: Application
    Filed: April 24, 2008
    Publication date: July 22, 2010
    Inventors: Philipp Wabnitz, Heike Schauerte, Hans Allgeier, Martin Augustin, Lutz Zeitlmann, Michael A. Pleiss, Gabriele Stumm, Anke Mueller
  • INHIBITORS OF PROTEIN KINASES
    Publication number: 20100184780
    Abstract: The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceuticals compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases. formula (I).
    Type: Application
    Filed: April 24, 2008
    Publication date: July 22, 2010
    Inventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
  • INHIBITORS OF PROTEIN KINASES
    Publication number: 20100168144
    Abstract: The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases. formula (I).
    Type: Application
    Filed: April 24, 2008
    Publication date: July 1, 2010
    Inventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
  • Methods of treating pain
    Publication number: 20090221581
    Abstract: The invention relates to methods of treating any type of pain comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
    Type: Application
    Filed: May 24, 2006
    Publication date: September 3, 2009
    Inventors: Philipp Wabnitz, Heike Schauerte, Gabriele Stumm, Joachim Freitag
  • Inhibitors of protein kinases
    Publication number: 20080275063
    Abstract: The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceutical compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.
    Type: Application
    Filed: April 24, 2007
    Publication date: November 6, 2008
    Inventors: Heike Schauerte, Hans Allgeier, Michael A. Pleiss, Martin Augustin, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz
  • Methods of treating pain
    Publication number: 20080188524
    Abstract: A method for the treatment of pain comprises administering a to a subject in need thereof an amount of at least one inhibitor of a cyclin-dependent kinase (CDK). Preferably, the inhibitor of a cyclin-dependent kinase comprises a thiazole of general Formula I, II or III as desribed herein.
    Type: Application
    Filed: October 24, 2007
    Publication date: August 7, 2008
    Inventors: Martin Augustin, Lutz Zeitlmann, Gabriele Stumm, Michael A. Pleiss, Philipp Wabnitz, Hans Allgeier
  • Methods of treating pain
    Publication number: 20080153822
    Abstract: The present invention provides compositions and methods for treating pain using a compound of general Formula I: wherein the substituents thereof are as described herein.
    Type: Application
    Filed: November 29, 2007
    Publication date: June 26, 2008
    Inventors: Martin Augustin, Gabriele Stumm, Hans Allgeier, Andreas Marquardt, Lutz Zeitlmann
  • Cytoplasmic dynein heavy chain 1 genes, expression products, non-human animal model uses in human neurological diseases
    Publication number: 20070010657
    Abstract: A non-human animal model is provided, particularly a mouse model for movement hyperactivity, excitoxicity disorders (e.g. myoclonic cramping) and neurodegeneration, in which modified cytoplasmic dynein heavy chain1 is expressed. Modified human and mouse cytoplasmic dynein heavy chain1 proteins and nucleic adds are also provided, including the corresponding recombinant proteins. The invention further provides uses for the non-human animal model and the modified cytoplasmic dynein heavy chain1 proteins and nucleic acids, in particular for the diagnosis and treatment of medical conditions associated with over-expression of cytoplasmic dynein heavy chain1.
    Type: Application
    Filed: September 11, 2003
    Publication date: January 11, 2007
    Inventors: Rainer Klocke, Andreas Marquardt, Gisela Peraus, Gabriele Stumm, Philipp Wabnitz